Schwank et al. conducted pioneering studies using CRISPR/Cas9 to correct the F508del mutation in the CFTR gene, resulting in improved functionality of the CFTR protein in intestinal organoids derived from CF patients [178]. This evidence concerns the gene CFTR and cystic fibrosis.